Publications by authors named "Laura A Kooienga"
Article Synopsis
- The PROTECT trial, a phase 3 study, evaluated the effectiveness of sparsentan, a dual receptor antagonist, in reducing proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.*
-
- A total of 406 patients were randomly assigned to either sparsentan or irbesartan, with the primary goal being the change in proteinuria at 36 weeks and secondary goals related to kidney function and safety over the trial duration.*
-
- The findings from the trial, which included a significant reduction in proteinuria with sparsentan, provide important insights into potential treatment strategies for patients with kidney conditions.*
N Engl J Med
December 2023
Article Synopsis
- - A phase 3 trial investigated the long-term effects of sparsentan versus irbesartan in treating focal segmental glomerulosclerosis (FSGS) over 108 weeks, enrolling 371 patients aged 8 to 75.
- - At 36 weeks, sparsentan showed a significantly higher rate of partial remission of proteinuria (42%) compared to irbesartan (26%), and this positive response continued up to 108 weeks.
- - However, there were no significant differences in the estimated glomerular filtration rate (eGFR) slopes between the two groups at the final analysis, indicating that while proteinuria improved, kidney function as measured by eGFR remained similar with both treatments. *
Nephrol Dial Transplant
September 2023
Article Synopsis
- Vadadustat is being studied as an oral alternative to injectable treatments for anemia in patients on peritoneal dialysis, showing comparable safety and efficacy to darbepoetin alfa in clinical trials.
- A post hoc analysis of the INNO2VATE trials indicated that for patients on peritoneal dialysis, the rates of major cardiovascular events and changes in hemoglobin levels were similar for both treatments.
- Adverse events were reported less frequently in the vadadustat group compared to the darbepoetin alfa group, suggesting a potentially safer profile for vadadustat in this population.
